1. Pink Sheet
  2. >>Geography
  3. >>Europe

New Data Means Successful Joint Pricing Talks For Orchard’s Libmeldy in Europe

 
• By Francesca Bruce

Orchard Therapeutics has secured reimbursement in Ireland, the Netherlands and Belgium nearly a year after the collapse of joint pricing talks between the company and the three countries.

Euros
Ireland, the Netherland and Belgium Agree on Price for Orchard's Costly Gene Therapy • Source: Shutterstock

Additional long-term data from Orchard Therapeutics has convinced Ireland, the Netherlands and Belgium to reimburse the company’s costly gene therapy Libmeldy (atidarsagene autotemcel). The three countries, working together under the BeNeLuxA cross-country initiative, had previously said the drug was too expensive.

“We are pleased to have reached an agreement with the BeNeluxA consortium that enables sustainable access to treatment. The agreement...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.